Navigation Links
EDARBYCLOR (azilsartan medoxomil and chlorthalidone) Now Available in U.S. Pharmacies for Patients with Hypertension
Date:2/6/2012

y blocking the action of angiotensin II, a vasopressor hormone, which naturally exists within the body. When EDARBI blocks the angiotensin II receptor, blood vessels can stay relaxed and open, and blood pressure can be reduced. EDARBI is indicated for the treatment of hypertension to lower blood pressure in adults, either alone or in combination with other antihypertensive agents. The recommended dose of EDARBI in adults is 80 mg taken once daily. A starting dose of 40 mg may be appropriate for patients on high doses of diuretics. EDARBI is approved in the United States, Europe and Mexico.

EDARBYCLOR (azilsartan medoxomil and chlorthalidone) is a fixed-dose combination therapy for the treatment of hypertension that combines azilsartan medoxomil and chlorthalidone in a single tablet. Chlorthalidone reduces the amount of water in the body by increasing the flow of urine, which helps lower blood pressure. EDARBYCLOR is indicated for the treatment of hypertension to lower blood pressure; it may be used in patients not adequately controlled with monotherapy and as an initial therapy if a patient is likely to need multiple drugs to achieve blood pressure goals. The recommended starting dose of EDARBYCLOR in adults is 40/12.5 mg taken orally once daily. The maximal dose is 40/25 mg.

Important Safety Information
Boxed Warning for FETAL TOXICITY

When pregnancy is detected, patients should discontinue EDARBI or EDARBYCLOR as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.

EDARBYCLOR is contraindicated in patients with anuria.

Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. When pregnancy is detected, patients should discontinue EDARBI or EDARBYCLOR as soon as possible. Thiazides cross the placental
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. FDA Approves EDARBYCLOR (azilsartan medoxomil and chlorthalidone) for the Treatment of Hypertension
2. EDARBI (azilsartan medoxomil), Now Available in U.S. Pharmacies for Patients With Hypertension
3. FDA Approves EDARBI (azilsartan medoxomil) for the Treatment of Hypertension
4. Takeda Submits New Drug Application in the U.S. for Azilsartan Medoxomil Plus Chlorthalidone, an Investigational Fixed-Dose Combination for the Treatment of Hypertension
5. New Data Shows AZOR(R) (amlodipine and olmesartan medoxomil) Significantly Improves 24-Hour Ambulatory Blood Pressure
6. New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering
7. NHS Makes £200 Non-Drug Hypertension Treatment Device Available on Prescription
8. PuraMed BioScience, Inc. Announces LipiGesic®M, Their Unique Migraine Treatment, is Now Available for Purchase at CVS, the 2nd Largest Drug Chain in the United States
9. Nearly 9 Million Kaiser Permanente Health Records Securely Available on Mobile Devices
10. Edgemont - New Fluoxetine Tablets, 60 mg Now Available
11. Simbionix Comprehensive Medical Simulators now Available in Additional Languages
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 According to a new ... Market (Endoscopes, Endoscopic Operative Devices, and Visualization Systems) - ... 2013-2019" the global endoscopy devices market was valued at ... grow at a CAGR of 6.8% from 2013 to ... billion in 2019. Browse the full Endoscopy ...
(Date:7/10/2014)... India , July 11, 2014  Major ... treatment of cancer are being highlighted in a ... Mumbai from 10-12 July, 2014.  Renowned national ... to share best practices and exchange knowledge on ... precise, accurate and efficient. The ...
(Date:7/10/2014)...  RESMED INC. (NYSE: RMD ) today announced ... ended June 30, 2014 results on Thursday, July 31, 2014, ... release with ResMed,s results will be issued after 1:00 p.m. ... to discuss operating results and future outlook. The ... Pacific Time and the live webcast of the call can ...
Breaking Medicine Technology:Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2
... Soligenix, Inc. (OTC Bulletin Board: SNGX ) ... today that it has appointed Kevin Horgan, MD, as ... Horgan is a board-certified gastroenterologist with a research background ... patients with inflammatory bowel disease, including graft-versus-host disease (GVHD). ...
... JOLLA, Calif., Feb. 1, 2011 Transdel Pharmaceuticals, ... a specialty pharmaceutical company focused on developing topically ... announced that the Company has been exploring strategic alternatives ... American MedTech Advisors and ESC Advisors, a division ...
Cached Medicine Technology:Soligenix Appoints Kevin Horgan, MD, as Chief Medical Officer 2Soligenix Appoints Kevin Horgan, MD, as Chief Medical Officer 3Soligenix Appoints Kevin Horgan, MD, as Chief Medical Officer 4Transdel Pharmaceuticals Announces Exploration of Strategic Alternatives 2Transdel Pharmaceuticals Announces Exploration of Strategic Alternatives 3
(Date:7/11/2014)... 2014 (HealthDay News) -- Children who have emergency ... complications and potentially even death than those who ... However, the Johns Hopkins researchers noted that ... researchers analyzed data on nearly 440,000 simple emergency ... over a 22-year period. The surgeries are ...
(Date:7/11/2014)... According to a new market research report “Internet ... (ZigBee, Z-Wave, Bluetooth, Wi-Fi, NFC, RFID), Application Vertical (Building ... & Geography - Global Trends & Forecasts to 2014 ... was worth $1029.5 Billion in 2013, and is expected ... CAGR of 4.08% from 2014 to 2020. , ...
(Date:7/11/2014)... The Miriam Hospital have found that people with ... rates of smoking than those without mobility impairments. ... to attempt quitting than those without mobility impairments, ... for this population. The study and its findings ... the American Journal of Public Health . ...
(Date:7/11/2014)... HealthDay Reporter THURSDAY, July 10, 2014 (HealthDay ... worldwide scourge of dengue fever was somewhat successful in a ... dengue fever in 56 percent of the 10,000 kids who ... than 88 percent of them from severe disease. In the ... death. "This vaccine has already proven to be safe," ...
(Date:7/11/2014)... 2014 Last month Watkins Insurance Group ... joins the agency as a specialist in insurance and ... a Bachelor’s Degree in Business Administration from Texas State ... will manage everything from performance and payment bonds, license ... specialized needs for those in the asphalt supplier industry. ...
Breaking Medicine News(10 mins):Health News:Emergency Surgeries on Weekends Riskier for Kids: Study 2Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Miriam Hospital study examines smoking prevalence 2Health News:Dengue Fever Vaccine Shows Some Promise in Trial 2Health News:Dengue Fever Vaccine Shows Some Promise in Trial 3
... 3 The following is being issued by The American ... by federally funded organizations operating in every state has had ... during a period when hospital performance improved faster than outpatient ... The annual National Healthcare Quality Report, just released by the ...
... treatment or not, study finds , WEDNESDAY, June 3 ... before a mammogram doesn,t lower the likelihood of being ... than 1,700 women aged 45 to 80 has found. ... women,s breasts -- and make mammograms harder to read," ...
... PLYMOUTH MEETING, Pa., June 3 /PRNewswire-Asia-FirstCall/ -- ... or the "Company") today announced,that it will be featured ... conference call series to discuss the impact of,China Healthcare ... will be hosted by Ding Ding, Ph.D., SIG,s senior ...
... , -- Record non-infant formula nutritional sales of $9.8 million ... Earnings per share of $0.33, an increase of 20% over last ... million (Year-to-date operating cash flow of $26 million) , -- Full ... pre-tax earnings growth of 10% to 15% over fiscal 2008 ...
... IMAGINE Software, a leading provider of ... within the IMAGINEradiology(TM) practice management system at IMAGINE,s 2009 ... , , The system received a number ... deployment and maintenance distribution through application virtualization; "I-Connect," ...
... of Obama and His Agenda; Jon Stewart Bests Stephen Colbert, ... 3 Progressives gathered at this week,s "America,s Future Now" ... ,s first 100 days, but they are very focused on ... straw poll of participants conducted by Greenberg Quinlan Rosner Research ...
Cached Medicine News:Health News:QIO Support Accelerates Hospital Improvement in Heart Care, Researchers Find 2Health News:Pausing Hormone Therapy Doesn't Cut Mammogram Recalls 2Health News:BMP Sunstone to be Featured on SIG's 'China Healthcare On Call' Conference Call Series 2Health News:Martek Announces Second Quarter 2009 Financial Results 2Health News:Martek Announces Second Quarter 2009 Financial Results 3Health News:Martek Announces Second Quarter 2009 Financial Results 4Health News:Martek Announces Second Quarter 2009 Financial Results 5Health News:Martek Announces Second Quarter 2009 Financial Results 6Health News:Martek Announces Second Quarter 2009 Financial Results 7Health News:Martek Announces Second Quarter 2009 Financial Results 8Health News:Martek Announces Second Quarter 2009 Financial Results 9Health News:Martek Announces Second Quarter 2009 Financial Results 10Health News:Martek Announces Second Quarter 2009 Financial Results 11Health News:Martek Announces Second Quarter 2009 Financial Results 12Health News:IMAGINE Software Unveils Advanced IMAGINEradiology(TM) Features 2Health News:'America's Future Now' Straw Poll: Progressives See Health Care Reform With Public Option As Top Priority 2
Flowmate makes portable uroflowmetry easy, accurate and dignified. Flowmate has automatic start and stop as well as simple and straightforward reporting from its own printer....
... a minimally invasive treatment for prostate and ... to use, SeedNet provides optimum accuracy, efficiency ... SeedNet is the new generation in cryotherapy ... the SeedNet system, produce iceballs of extreme ...
Li Brand™ Surgical Hemostat. ("dissecting clamp") For NSV and other procedures....
No Scalpel Vasectomy Ring Clamp, 5 1/2" (14cm), gold finger rings...
Medicine Products: